Garsorasib API (CAS No. 2559761-14-5) is a synthetic small-molecule targeted oncology active pharmaceutical ingredient associated with KRAS G12C-mutated cancer pharmaceutical development.
Garsorasib, also known by the development code D-1553, is an orally active and selective inhibitor of the oncogenic KRAS G12C mutant protein.
KRAS is a small GTPase involved in intracellular signaling pathways that regulate cell growth, proliferation, and survival. The KRAS G12C mutation substitutes glycine with cysteine at amino acid position 12 and may contribute to persistent oncogenic signaling in susceptible tumor cells.
Garsorasib covalently binds to the cysteine residue of GDP-bound KRAS G12C and stabilizes the mutant protein in an inactive state. This inhibits KRAS-dependent downstream signaling pathways associated with tumor-cell proliferation and survival.
Pharmaceutical companies sourcing Garsorasib API commonly evaluate assay, HPLC purity, stereochemical identity, chiral purity, related substances, process-related impurities, degradation products, residual solvents, water content, crystalline form, particle size distribution, and batch-to-batch consistency.
Because Garsorasib is a covalent targeted inhibitor with defined stereochemical characteristics, control of enantiomeric impurities, electrophilic warhead-related degradation, process impurities, and solid-state properties is important during API qualification.
Particle size distribution and crystalline characteristics may also influence dissolution, formulation processing, and oral solid dosage-form development.
Swapnroop Drugs and Pharmaceuticals supplies Garsorasib API for qualified pharmaceutical research, targeted oncology drug development, analytical, formulation development, and regulated manufacturing requirements with product-specific quality documentation, pharmaceutical-grade packaging, and reliable supply-chain coordination.
Pharmaceutical companies evaluating Garsorasib API commonly focus on:
Stereochemical consistency is an important quality consideration for Garsorasib API because the molecular structure contains defined stereochemical configurations.
Control of the covalent-binding electrophilic functionality and related degradation products may also be evaluated during API development and stability studies.
Garsorasib API is primarily associated with:
Garsorasib-related pharmaceutical products are associated with targeted treatment strategies for tumors harboring the KRAS G12C mutation.
Garsorasib is designed to selectively inhibit the oncogenic KRAS G12C mutant protein.
Pharmaceutical companies evaluating Garsorasib API may review:
Product-specific API specifications should be evaluated according to the intended dosage form, formulation process, target regulatory market, and approved pharmaceutical development requirements.
KRAS cycles between active GTP-bound and inactive GDP-bound conformational states.
The KRAS G12C mutation introduces a cysteine residue at amino acid position 12.
Garsorasib selectively binds covalently to GDP-bound KRAS G12C and stabilizes the mutant protein in its inactive state.
This reduces KRAS G12C-mediated downstream oncogenic signaling associated with tumor-cell proliferation, survival, invasion, and disease progression.
The selective covalent targeting strategy is designed to inhibit mutant KRAS G12C while minimizing direct binding to wild-type KRAS.
Garsorasib is associated with oral targeted oncology pharmaceutical development.
Formulation-development considerations may include:
Particle-size-controlled or solid-state-specific API requirements should be confirmed according to the intended formulation and approved product specification.
Garsorasib and D-1553 refer to the same active pharmaceutical compound.
D-1553 was used as the development code during clinical development.
Garsorasib is the recognized drug name for the KRAS G12C inhibitor.
Procurement, formulation, quality, and regulatory teams should use CAS No. 2559761-14-5 to confirm the exact Garsorasib chemical identity.
Swapnroop Drugs and Pharmaceuticals supports qualified pharmaceutical and oncology-development customers with:
Garsorasib API is supplied in secure pharmaceutical-grade packaging selected according to product quantity, stability requirements, moisture protection requirements, and customer specifications.
Product-appropriate inner packaging and approved pharmaceutical-grade outer containers may be used according to the supplied material specification.
Available packaging configurations may include:
Packaging configuration, MOQ, commercial quantity, particle size requirements, and shipment conditions are confirmed according to the approved product specification and customer enquiry.
Store Garsorasib API in tightly closed and appropriately labeled containers under the controlled storage conditions specified in the approved product documentation.
Protect the material from excessive moisture, heat, direct light, oxidation, and unsuitable environmental exposure.
Handling should be performed by trained personnel using approved pharmaceutical and potent compound handling procedures, appropriate containment practices, and applicable safety documentation.
Product-specific storage and handling requirements should be confirmed from the approved COA, SDS, specification, and stability documentation.
Swapnroop Drugs and Pharmaceuticals provides Garsorasib API bulk supply and export support in India for qualified pharmaceutical manufacturers, targeted oncology drug developers, analytical laboratories, formulation-development organizations, research companies, and pharmaceutical procurement customers.
For Garsorasib API price, CAS No. 2559761-14-5, HPLC purity, chiral purity, related substance profile, COA availability, MOQ, particle size, packaging, and export enquiries, contact our pharmaceutical sales team.
Get Bulk Quote via WhatsApp